Leerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28

Benzinga Newsdesk www.benzinga.com Positive 61.9%

Neg 0% Neu 0% Pos 61.9%

Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.